Multiple myeloma (MM) stem cells, proposed to be responsible for the tumourigenesis, drug resistance and recurrence of this disease, are enriched in the cancer stem cell-like side population (SP). Cancer testis antigens (CTA) are attractive targets for immunotherapy because they are widely expressed in cancers but only in limited types of normal tissues. We designed a high throughput assay, which allowed simultaneous relative quantifying expression of 90 CTA genes associated with MM. In the three MM cell lines tested, six CTA genes were over-expressed in two and LUZP4 and ODF1 were universally up-regulated in all three cell lines. Subsequent study of primary bone marrow (BM) from eight MM patients and four healthy donors revealed that 19 CTA genes were up-regulated in SP of MM compared with mature plasma cells. In contrast, only two CTA genes showed a moderate increase in SP cells of healthy BM. Furthermore, knockdown using small interfering RNA (siRNA) revealed that LUZP4 expression is required for colony-forming ability and drug resistance in MM cells. Our findings indicate that multiple CTA have unique expression profiles in MM SP, suggesting that CTA may serve as targets for immunotherapy that it specific for MM stem cells and which may lead to the longterm cure of MM.
Summary
Multiple myeloma (MM) stem cells, proposed to be responsible for the tumourigenesis, drug resistance and recurrence of this disease, are enriched in the cancer stem cell-like side population (SP). Cancer testis antigens (CTA) are attractive targets for immunotherapy because they are widely expressed in cancers but only in limited types of normal tissues. We designed a high throughput assay, which allowed simultaneous relative quantifying expression of 90 CTA genes associated with MM. In the three MM cell lines tested, six CTA genes were over-expressed in two and LUZP4 and ODF1 were universally up-regulated in all three cell lines. Subsequent study of primary bone marrow (BM) from eight MM patients and four healthy donors revealed that 19 CTA genes were up-regulated in SP of MM compared with mature plasma cells. In contrast, only two CTA genes showed a moderate increase in SP cells of healthy BM. Furthermore, knockdown using small interfering RNA (siRNA) revealed that LUZP4 expression is required for colony-forming ability and drug resistance in MM cells. Our findings indicate that multiple CTA have unique expression profiles in MM SP, suggesting that CTA may serve as targets for immunotherapy that it specific for MM stem cells and which may lead to the longterm cure of MM.
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Multiple myeloma (MM) is the second most common haematological cancer and represents 10% of all haematopoietic malignancies in the United States (Jemal et al, 2007) . In 2010, the National Cancer Institute reported 20 180 new cases of MM and 10 650 deaths directly attributed to MM (Cruz et al, 2011) . Despite recent major improvements in treatment, MM still remains incurable and long-term survival appears elusive (Chanan-Khan et al, 2010; Borrello, 2012) . Current therapy focuses on killing the myeloma cells with cytotoxic agents, targeting myeloma cell-specific pathways, or inhibiting the myeloma-dependent microenvironment. Although these therapies can lead to initial complete clinical response, the majority of patients develop relapsed disease with resistance to these therapies (Munshi et al, 2002; Richardson et al, 2003) . This has led to the hypothesis that myeloma stem cell-like cells, which have increased resistance to many cytotoxic agents and possess self-renewal capacity, may be responsible for the relapsed disease (Hajek et al, 2013) .
Additional methods are required to eliminate the myeloma stem cells for the long-term cure of MM.
Cancer testis antigens (CTA) are a promising class of tumour antigens for T-cell-mediated immunotherapy due to their limited expression in somatic tissue. An earlier study demonstrated that CTA could be specifically recognized in vitro by cytotoxic T-cells (CTLs) in patients with melanoma (van der Bruggen et al, 1991) . Since then, more and more CTA genes have been characterized and tested as potential targets for cancer therapy (de Carvalho et al, 2012; Mengus et al, 2013) . Furthermore, another recent study showed that CTA genes were highly and frequently expressed in glioma cancer stem cells compared with differentiated cells (Yawata et al, 2010) . Encouraged by previous reports, we hypothesized that CTA genes may have a different expression profile in myeloma stem cells compared to mature plasma cells (MPC) and the over-expressed CTA genes may become ideal targets for immunotherapy for the elimination of myeloma stem cells.
In present study, based on gene expression data from MM and normal samples, we designed a high throughput quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay to simultaneously measure the expression of 90 CTA genes associated with MM. We identified several CTA genes whose expressions are increased in the MM SP. Furthermore, we found that one of those up-regulated CTA genes, LUZP4, is required for colony forming and drug resistance in MM cells. These findings will lead to the development of new CTL-mediated therapies by targeting these CTA genes, for the benefit of MM patients.
Material and methods

Cell cultures and reagents
Multiple myeloma cell lines RPMI8226, MM1S and U266 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were grown in RPMI 1640 medium (Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, GA, USA), 100 u/ml penicillin and 100 lg/ml streptomycin (Thermo Fisher Scientific, Houston, TX, USA), as previously reported (Wen et al, 2011) .
Bone marrow (BM) aspirates were collected from eight MM patients and four healthy donors under a protocol approved by the Houston Methodist Research Institute and informed consent was obtained, in compliance with the Declaration of Helsinki. Primary cells were purified from freshly isolated BM by Ficoll (MP Biomedicals, Solon, OH, USA) density sedimentation. Cells were cultured in RPMI 1640 medium containing 10% FBS, 100 u/ml penicillin, 100 lg/ml streptomycin and 2 mmol/l-glutamine, and maintained at 37°C in 5% CO 2 .
All chemicals, unless otherwise stated, were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).
SP analysis and cell sorting by flow cytometry
To identify the SP in MM cell lines, cells were seeded at 0Á5 9 10 6 cells/ml in a T75 flask for 3 d (72 h after seeding)
in RPMI 1640 medium with 10% FBS, supplemented with 100 u/ml penicillin and 100 lg/ml streptomycin. Cells were harvested and washed in pre-warmed RPMI 1640 medium with 2% FBS and 10 mmol/l HEPES buffer, and then resuspended at a concentration 1 9 10 6 cells/ml in RPMI 1640 medium with 2% FBS and 10 mmol/l HEPES. Hoechst 33342 water solution (1 mg/ml) was then added to make a final concentration of 5 lg/ml followed by incubation in a water bath at 37°C for 90 min with shaking every 15 min. Immediately after incubation, the samples were put on ice to stop dye efflux and washed with ice-cold Hank's balanced salt solution (HBSS) containing 2% FBS and 10 mmol/l HE-PES. Subsequently, Hoechst-labelled cells were stained with CD138-PE monoclonal antibody (BD Biosciences, San Jose, CA, USA) for 15 min on ice.
To identify the SP in primary samples, cells were harvested and washed in pre-warmed RPMI 1640 medium with 2% FBS and 10 mmol/l HEPES buffer. SP staining was performed as for the cell lines.
Cells were then analysed using FACS Aria (Becton Dickinson, San Jose, CA, USA). The Hoechst 33342 dye was excited at 357 nm and its fluorescent emission was measured at Hoechst blue fluorescence and Hoechst red fluorescence. SP cells and mature plasma cells (i.e., CD138-positive non-SP cells) were then sorted accordingly (Fig 1) .
Aldefluor assay by flow cytometry
Aldefluor assay was performed according to the manufacturer's instruction (Stem Cell Technologies, Vancouver, BC, Canada). The aldehyde dehydrogenase (ALDH) high and low populations of RPMI8226 cells were analysed and sorted with the FACS Aria.
cDNA synthesis cDNA from sorted cells was synthesized with the WT-Ovation RNA Amplification System (Nugen, San Carlos, CA, USA) according to the user's guide. The cDNA concentration was estimated using the NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
CTA gene selection
Cancer testis antigens expression in various types of cancers should be different. In order to identify CTA signatures in MM among different stage MM patients, we used the open access microarray database: Mayo Clinic MM Microarray. This database was established by analysing BM samples of 91 new, 23 smouldering and 26 relapsed MM patients from MM research consortium (MMRC, http://www.broadinstitute.org/ mmgp/home). Then, we integrated this database with the CTA gene bank database (http://www.cta.lncc.br/) to specifically study the expression of CTA genes in MM patients and identified 90 CTA genes expressed by the majority of MM patients (Fig 2A) .
Primers and qRT-PCR
We designed primers for these 90 CTA and 5 housekeeping genes (data not shown) using Primer 3 software and selected those that contained at least 1 exon-exon junction to reduce the genomic DNA contamination. One pair of primers for each gene was added to each well of a 96-well plate to form the assay, comprising 90-CTA genes and 5 housekeeping genes, and one well as a blank control without any primer. qRT-PCR analysis of the gene expression was then performed using RT 2 -SYBR â Green PCR Master Mix (Qiagen, Valencia, CA, USA) with 40 cycles of 15 s at 95°C and 1 min at 58°C on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Fluorescence data were collected at 58°C after each cycle. After the final cycle, melting curve analysis of all samples was conducted within the range of 58-95°C. The specificity of the PCR products was verified by the targeted product size using gel electrophoresis and melting curve analysis. The threshold cycle and 2 ÀDDCt method were used for calculating the relative amount of the target RNA using the average of the five house-keeping genes as internal control, according to user's manual. The experiments were repeated in triplicate.
Immunoglobulin heavy chain (IGH) gene rearrangement analysis
DNA was isolated from cells using the QIAmp system (Qiagen). The concentration of DNA was estimated using the NanoDrop ND-1000 spectrophotometer. DNA quality was assessed using Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA, USA). PCR primer sequences for IGHV gene framework region 3 (FR3) were designed as previously reported (Kummalue et al, 2010) . PCR of the IGH genes to assess clonality used the BIOMED-2 system. Master mixes were purchased from Invivoscribe Technologies (San Diego, CA, USA), and the PCR was done as per manufacturer's instructions and used HotStart Taq DNA polymerase (Qiagen) (Burack et al, 2010) .
Immunofluorescence SP and non-SP (NSP) cells were sorted with Hoechst 33342 staining. After washing, cells were resuspended in phosphate-buffered saline (PBS) and transferred to a coverslip coated with poly-L-lysine. After a 1-h incubation at room temperature, excess cell suspension was removed. Cells were washed, fixed, blocked with PBS containing 0Á1% bovine serum albumin, and incubated with primary anti-AURKA antibody (Thermo Fisher Scientific) for 1 h. Subsequently, cells were washed with PBS and incubated with TXRed-labelled secondary antibody. After washing, coverslips were mounted on slides in fluorescent mounting medium containing 4',6-diamidino-2-phenylindole (DAPI) (ProLong antifade reagent with DAPI; Invitrogen, Carlsbad, CA, USA). Fluorescence was detected using an Olympus microscope and images were acquired using Cellsens Dimension software.
SiRNA knock down LUZP4 gene siRNA and scrambled siRNA (Santa Cruz Biotechnology, Dallas, TX, USA) were used at 100 nmol/l to transfect RPMI8226 cells using Lipofectamine RNAiMAX (Invitrogen), as previously reported (Wen et al, 2008) . Knockdown efficiency of siRNAs was confirmed by Western blot analysis.
Western blotting
Cell lysates were prepared and analysed by Western blot as described previously. The membrane was probed with antibody to LUZP4 (Santa Cruz Biotechnology). After detection, the membrane was completely stripped and ACTB (b-actin) was used as loading control (Wen et al, 2008) .
Cell colony assay
A soft agar colony assay was performed as previously reported (Wen et al, 2011) . Briefly, 1Á5 ml base agar layers of 0Á6% agarose were prepared in 35 mm dishes by combining equal volumes of 1Á2% low melting temperature agarose (Thermo Fisher Scientific) and 29 RPMI 1640 medium + 20% FBS + 29 antibiotics. Next, 5 9 10 3 cells were resuspended in 0Á75 ml 29 RPMI 1640 medium + 20% FBS + 29 antibiotics and mixed with 0Á75 ml volumes of 0Á6% agar, then immediately plated on top of base agar. Complete medium was added on the top and changed twice a week. After 2 weeks, dishes were stained with methylene blue, pictures were taken under a phase contrast microscope, and colony number was counted.
Flow cytometric analysis of apoptosis
Cells were treated with arsenic trioxide (Sigma-Aldrich Co.) or Bortezomib (Millennium Pharmaceuticals, Cambridge, MA, USA) for 24 h. Dual staining with Annexin V-fluorescein isothiocyanate (FITC) and PI (Propidium iodide) (Becton Dickinson) was used to detect apoptosis according to the manufacturer's instructions as previously reported (Wen et al, 2008 (Wen et al, , 2010 .
Statistical analysis
Statistical analysis was conducted with the SPSS 10 SPSS Inc., Chicago, IL, USA), using t-test or 1-way analysis of variance (ANOVA) where appropriate.
Results
SP cells from myeloma patients containing clonal population
The flow cytometric analysis revealed that in primary MM patient BM, SP cells are CD138-negative and NSP cells are CD138+ (Fig 1A, B) . Immunoglobulin heavy chain (IGH) rearrangement study showed that SP and MPC from myeloma patients possess the identical IGH rearrangement pattern ( Fig 1C) . This result indicates that the SP of these patients contains myeloma stem cells that are of same cell origin of the mature neoplastic plasma cells.
MM-CTA were enriched in SP in MM cell lines
With the strategy shown in Fig 2A, we designed the MMspecific CTA gene assay composed of 90 CTA genes and 5 housekeeping genes. Among these 90 CTA genes, 5 genes were up-regulated in the new MM patient and 4 genes were up-regulated in the patient with smouldering MM. Futhermore, 17 CTA genes were up-regulated in relapsed MM patient, compared with normal control (Fig 2B) . The expression levels as well as the ratio to normal control in relapsed MM, smouldering MM, and new MM are shown in Table I . To test if CTA gene expression is enriched in MM SP, we investigated the CTA expression profile in various myeloma cell lines and primary samples. We collected SP and MPC, respectively, from MM cells lines including RPMI8226, MM1S and U266. Using a threshold of >2-fold change for genes expression (SP: MPC) and P value < 0Á05 after t-test, 16 CTA genes were up-regulated in RPMI8226 (Fig 3A) , 13 CTA genes in MM1S (Fig 3B) and 11 CTA genes in U266 cell line (Fig 3C) . Of note, among these genes, GAGE12F, MAGEA4, MAGEA5, SSX1, and TOP2A genes showed overlap in 2 of 3 cell lines, and LUZP4 and ODF1 were universally up-regulated in all 3 MM cell lines. Furthermore, Immunofluorescence membrane staining with anti-CTA antigen AURKA antibody was performed. In agreement with our PCR data, the AURKA antibody stain showed higher membrane expression in SP cells than in MPC ( Figure S1 ).
MM-CTA were enriched in SP in MM BM samples
We further extended our study to primary MM cells. Nineteen CTA genes were significantly up-regulated in SP (fold change >2 compared with MPC, P < 0Á05, t-test); Fig 4A. Interestingly, AURKA, DDX43, FANCI, MAGEA3, TEX14, and LUZP4 were also identified as up-regulated genes in the SP of at least 1 MM cell line. In addition, 3 CTA genes (AKAP4, MAGEA3, and SSX2) and 7 genes (ANKRD45, FANCI, LUZP4, MAGEA12, MAGEB3, RRM2, and TEX14) were over-expressed by the SP of 8/8 and 7/8 MM patients, respectively (Table II) . The detailed information for MM patients and fold-change of CTA gene in each patient are shown in Tables SI and SII, respectively.
In contrast to MM BM, only 2 CTA genes, DUT and KDM5B (JARID1B), showed moderate increase (2Á2-and 4Á5-fold, respectively) in the SP of normal BM compared with MPC ( Fig 4B) . Of interest, these 2 genes were not up-regulated in the SP of MM patients. Additionally, except for AKAP4 (3Á95-fold), CFLAR (2Á93-fold), HIST1H2BG (2Á24-fold), MAGEB2 (4Á18-fold) and MAGEB3 (3Á97-fold), the expression level of 19 up-regulated CTA genes in SP of MM BM was more than 5 times higher than that in SP of normal BM control (Fig 4C) .
It should be noted that the SP cells in the myeloma patients include both cancer stem cells and normal haematopoietic stem cells (HSC) while the SP cells in normal samples contain only normal HSC (Morita et al, 2006; Golebiewska TSPY1  1Á31  144Á17  109Á72  0Á0153  2Á7917  2Á12  0Á9802  4Á59  3Á50  0Á9482  CTAG2  1Á00  37Á10  37Á10  0Á0085  2Á5458  2Á55  0Á9114  8Á42  8Á42  0Á5272  CTAG1B  1Á42  28Á10  19Á85  0Á0071  2Á7200  1Á92  0Á8962  7Á24  5Á11  0Á4917  MAGEA6  10Á93  130Á44  11Á94  0Á0013 21Á6263  1Á98  0Á7747  64Á96  5Á94  0Á0890  SSX2  1Á01  8Á55  8Á45  0Á0189  1Á2571  1Á24  0Á1563  2Á11  2Á08  0Á6910  XAGE1  7Á58  36Á04  4Á76  0Á0019 11Á9171  1Á57  0Á6385  20Á91  2Á76  0Á0893  MORC1  3Á91  17Á00  4Á35  0Á0029  7Á5021  1Á92  0Á4167  11Á60  2Á97  0Á0411  MAGEA3  48Á13  185Á84  3Á86  0Á0019 52Á0454  1Á08  0Á9301 107Á98  2Á24  0Á1143  SSX1  16Á89  50Á74  3Á00  0Á0040 16Á5313  0Á98  0Á9699  25Á28  1Á50  0Á2981  MAGEA5  3Á31  8Á73  2Á64  0Á0010  4Á1242  1Á25  0Á621  4Á67  1Á41  0Á3306  NOL4  37Á95  96Á46  2Á54  0Á0331 76Á7538  2Á02  0Á1651  81Á43  2Á15  0Á0666  AKAP4  13Á86  33Á80  2Á44  0Á0026 44Á8713  3Á24  ≤0Á0001  34Á75  2Á51  0Á0003  MAGEA4  14Á03  33Á62  2Á40  0Á0110 16Á2088  1Á16  0Á7799  18Á81  1Á34  0Á4689  MAGEA9  27Á88  61Á35  2Á20  ≤0Á0001 37Á2521  1Á34  0Á1752  45Á94  1Á65  0Á0023  MAGEC1  46Á81  101Á80  2Á17  0Á0392 95Á0188  2Á03  0Á0764 112Á94  2Á41  0Á0044  TTK  9Á41  20Á15  2Á14  0Á0177 11Á1225  1Á18  0Á7063  13Á38  1Á42  0Á3062  MAGEB4  6Á06  12Á43  2Á05  0Á0245 14Á0083  2Á31  0Á0062  8Á76  1Á45 . Thus, the differences of CTA expression between the SP cells of myeloma patients and controls are most probably due to the increased expression of CTA genes of cancer stem cells within the SP cells of myeloma patients. All these results suggested that CTA have unique expression profiles in the SP of MM cells, suggesting that CTA may serve as targets for immunotherapy that is specific for MM stem cells, which may lead to the long term cure of MM.
LUZP4 gene expression is required for colony formation and drug resistance
To explore the function of the gene LUZP4, which was universally up-regulated in SP of MM cell lines and primary MM BM, we used siRNA to knockdown gene expression and the efficiency was confirmed by Western blot (Fig 5A) . Given its up-regulated expression level in MM stem cells, which play a critical role in tumour development, disease recurrence, resistance and chemotherapy Matsui et al, 2008; Brennan & Matsui, 2009; Ghosh & Matsui, 2009; Jakubikova et al, 2011; Paino et al, 2012) , we hypothesized that the function of LUZP4 may be related to colony forming ability and drug resistance. Firstly, the LUZP4 siRNA knocked-down U266 cells and control cells were grown on agar for 2 weeks: the results showed that LUZP4 knocked-down cells formed fewer colonies compared to control cells. Next, we treated the LUZP4 knocked-down U266 cells with arsenic trioxide and bortezomib for 24 h and the results showed that LUZP4 knocked-down U266 cells were more sensitive to chemotherapy. 
Discussion
Our results have indicated that certain CTA genes (e.g., AU-RKA, DDX43, FANCI, MAGEA3, TEX14 and LUZP4) are upregulated in both SP cells of the majority of MM cell lines and primary marrow samples from MM patients compared to the mature myeloma cells. This finding indicates that upregulation of CTA genes is a common feature for myeloma cells with stem cell features. This is in accordance with previous reports showing that enhanced expression of CTA genes in glioma stem cells and that CTA genes promoters may be tightly regulated by methylations and the methylation levels in promoter regions in cancer stem cells are lower than that in differentiated cells (Yawata et al, 2010) . This mechanism may have contributed to the up-regulation of CTA in cancer stem cells in general and in myeloma stem cells in our study. In this study, we used SP cells identified by flow cytometry, based on the unique property of stem cells, which pump out Hoechst 33342 dye due to their high expression of ATP binding cassette transporters, to identify myeloma stem cells in MM. This is because studies have demonstrated that SP cells exhibited clonogenic and tumourigenic potential in MM (Jakubikova et al, 2011; Ikegame et al, 2012) . We did not use surface markers, another commonly used approach to study cancer stem cells, because the surface marker phenotype for myeloma stem cells remains controversial (Yaccoby & Epstein, 1999; Matsui et al, 2008; Jakubikova et al, 2011) . Similar to the previous study (Jakubikova et al, 2011) , we demonstrated an identical IGH gene rearrangement pattern in the SP cells and mature neoplastic plasma cells (Fig 1) , confirming that our methodology is adequate to identify the myeloma stem cells from marrow samples of myeloma patients. In contrast, clonal IGH rearrangement was absent in the SP and mature plasma cells of controls when using an identical approach, indicating a lack of clonal populations (data not shown). Additionally, we used another function assay, ALDEFLUOR, for identifying and isolating stem cells of a myeloma cell line (RPMI8226) based on the high expression of aldehyde dehydrogenase of stem cells Brennan et al, 2010) . The stem cells isolated using this functional assay showed similarly elevated CTA expression as isolated by SP cells, confirming that the overexpression of CTA is unique character of myeloma stem cells ( Figure S2) .
Of the CTA genes up-regulated among the SP of MM, LUZP4, MAGEA12, MAGEA3, MAGEB2, MAGEB3, and SSX2, have particular potential for consideration as targets for immunotherapy targeting the myeloma stem cell-like cells. These CTA genes are localized to the X-chromosome (Table II) . As shown by previous studies (Dakshinamurthy et al, 2008) , CTA genes localized to this chromosome are highly immunogenic; in contrast, immunogenicity of CTA localized on autosomal chromosomes has not been proven (Scanlan et al, 2004) .
It is worth noting that this study included 8 MM patients (Tables SI, SII) ; however, it remains difficult to link CTA gene expression profile to the different stages of MM. We believe that more MM cases are required to shed the light on this task.
Immunotherapy, targeting myeloma stem cell-like cells expressing CTA, is particularly attractive for MM patients who have achieved complete remission. The majority, if not all, of these patients developed recurrent disease that is resistant to multiple agents. It has been proposed that the myeloma stem cells, which are highly drug-resistant in nature and have self-renewal capability, play a critical role in the recurrence of MM. This immunotherapy approach is likely to eradicate the myeloma stem cells in these patients to ensure long-term remission of these patients. In our previous studies, we have demonstrated the feasibility of this approach and showed that cytotoxic T-cells (CTL) specific for PRAM-E-derived peptide can target leukaemic and leukaemic-precursor cells expressing PRAME (Quintarelli et al, 2011) .
Additionally, previous studies have suggested that some CTA genes may function as regulators of cell-cycle progression, apoptosis and transcriptional repression (Scanlan et al, 2002; Yawata et al, 2010) . CTA genes may thus participate in maintaining the stem cell pool directly or indirectly. In the present study, knock down LUZP4 expression with siRNA reduced the colony-forming ability of MM cells and sensitized the cells to chemotherapy. This finding will initiate further investigation regarding the function of CTA genes in MM.
In summary, the current study identifies a subset of CTA genes highly expressed by multiple myeloma stem cell-like side population cells using a unique high throughput Table II . Up-regulated cancer testis antigen (CTA) genes in bone marrow from primary multiple myeloma patients. The up-regulated CTA genes in the side population of each multiple myeloma patient, as compared with mature plasma cells, is indicated by "↑".
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Multiple myeloma cases Symbol Location 1 2 3 4 5 6 7 8 qRT-PCR assay designed in our laboratory. The resulting data provides the framework for using immunotherapy to target the myeloma stem cells expressing high levels of CTA for the long-term cure of MM. 
